Kleinclauss Francois, Fauda Martin, Sutherland David E R, Kleinclauss Colette, Gruessner Rainer W, Matas Arthur J, Kasiske Bertram L, Humar Abhinav, Kandaswamy Raja, Kaul Suruchi, Gruessner Angelika C
Department of Surgery, Division of Renal Disease and Hypertension, University of Minnesota, Minneapolis, MN, USA.
Clin Transplant. 2009 Aug-Sep;23(4):437-46. doi: 10.1111/j.1399-0012.2009.00998.x. Epub 2009 Jun 2.
In this single-institution study, we compared outcomes in diabetic recipients of living donor (LD) kidney transplants that did vs. did not undergo a subsequent pancreas transplant. Of 307 diabetic recipients who underwent LD kidney transplants from January 1, 1995, through December 31, 2003, a total of 175 underwent a subsequent pancreas after kidney (PAK) transplant; 75 were deemed eligible (E) for, but did not receive (for personal or financial reasons), a PAK, and thus had a kidney transplant alone (KTA); and 57 deemed ineligible (I) for a PAK because of comorbidity also had just a KTA. We analyzed the three groups (PAK, KTA-E, KTA-I) for differences in patient characteristics, glycemic control, renal function, patient and kidney graft survival rates, and causes of death. Kidney graft survival rates (actuarial) were similar in the PAK vs. KTA-E groups at one, five, and 10 yr post-transplant: 98%, 82%, and 67% (PAK) vs. 100%, 84%, and 62% (KTA-E) (p = 0.9). The long-term (greater than four yr post-transplant) estimated glomerular filtration rate (GFR) was higher in the PAK than in the KTA-E group: 53 +/- 20 mL/min (PAK) vs. 43 +/- 16 mL/min (KTA-E) (p = 0.016). The patient survival rates were also similar for the PAK and KTA-E groups. We conclude that the subsequent transplant of a pancreas after an LD kidney transplant does not adversely affect patient or kidney graft survival rates; in fact, it is associated with better long-term kidney graft function.
在这项单中心研究中,我们比较了接受活体供肾(LD)移植的糖尿病受者后续接受或未接受胰腺移植的结局。在1995年1月1日至2003年12月31日期间接受LD肾移植的307例糖尿病受者中,共有175例在肾移植后接受了后续的胰肾联合移植(PAK);75例被认为符合胰肾联合移植条件(E),但因个人或经济原因未接受(仅接受了肾移植,即KTA);57例因合并症被认为不符合胰肾联合移植条件(I),也仅接受了肾移植。我们分析了三组(PAK、KTA-E、KTA-I)在患者特征、血糖控制、肾功能、患者及肾移植存活率以及死亡原因方面的差异。移植后1年、5年和10年时,PAK组与KTA-E组的肾移植存活率(精算)相似:分别为98%、82%和67%(PAK组)与100%、84%和62%(KTA-E组)(p = 0.9)。移植后长期(超过4年)的估计肾小球滤过率(GFR),PAK组高于KTA-E组:53±20 mL/min(PAK组)与43±16 mL/min(KTA-E组)(p = 0.016)。PAK组和KTA-E组的患者存活率也相似。我们得出结论,LD肾移植后再进行胰腺移植不会对患者或肾移植存活率产生不利影响;事实上,它与更好的长期肾移植功能相关。